These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in type 2 diabetic nephropathy. Futrakul N; Butthep P; Vongthavarawat V; Futrakul P; Sirisalipoch S; Chaivatanarat T; Suwanwalaikorn S Clin Hemorheol Microcirc; 2006; 34(3):373-81. PubMed ID: 16614461 [TBL] [Abstract][Full Text] [Related]
10. Early stage of vascular disease and diabetic kidney disease: an under-recognized entity. Futrakul N; Chanakul A; Futrakul P; Deekajorndech T Ren Fail; 2015; 37(8):1243-6. PubMed ID: 26365595 [TBL] [Abstract][Full Text] [Related]
11. Renal microvascular disease in an aging population: a reversible process? Futrakul N; Futrakul P Ren Fail; 2008; 30(4):353-6. PubMed ID: 18569906 [TBL] [Abstract][Full Text] [Related]
12. Increased circulating trimethylamine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease. Li T; Gua C; Wu B; Chen Y Biochem Biophys Res Commun; 2018 Jan; 495(2):2071-2077. PubMed ID: 29247650 [TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and hemodynamic maladjustment in chronic renal disease: a therapeutic implication. Futrakul N; Tosukhowong P; Valyapongpichit Y; Tipprukmas N; Futrakul P; Patumraj S Ren Fail; 2002 Jul; 24(4):433-45. PubMed ID: 12212823 [TBL] [Abstract][Full Text] [Related]
14. Altered vascular homeostasis in type 2 diabetic nephropathy. Futrakul N; Butthep P; Futrakul P Ren Fail; 2009; 31(3):207-10. PubMed ID: 19288326 [TBL] [Abstract][Full Text] [Related]
15. Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat. Eyre HJ; Speight T; Glazier JD; Smith DM; Ashton N Exp Physiol; 2019 Mar; 104(3):421-433. PubMed ID: 30575177 [TBL] [Abstract][Full Text] [Related]
16. FGF23 impairs peripheral microvascular function in renal failure. Verkaik M; Juni RP; van Loon EPM; van Poelgeest EM; Kwekkeboom RFJ; Gam Z; Richards WG; Ter Wee PM; Hoenderop JG; Eringa EC; Vervloet MG; Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1414-H1424. PubMed ID: 30028196 [TBL] [Abstract][Full Text] [Related]
17. Treatment of glomerular endothelial dysfunction in steroid-resistant nephrosis with Ganoderma lucidum, vitamins C, E and vasodilators. Futrakul N; Boonyen M; Patumraj S; Siriviriyakul P; Tosukhowong P; Futrakul P Clin Hemorheol Microcirc; 2003; 29(3-4):205-10. PubMed ID: 14724343 [TBL] [Abstract][Full Text] [Related]
18. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Rastogi A Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730 [TBL] [Abstract][Full Text] [Related]
19. Contribution of genetics and epigenetics to progression of kidney fibrosis. Tampe B; Zeisberg M Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv72-9. PubMed ID: 23975750 [TBL] [Abstract][Full Text] [Related]
20. The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice. Sogawa Y; Nagasu H; Itano S; Kidokoro K; Taniguchi S; Takahashi M; Kadoya H; Satoh M; Sasaki T; Kashihara N PLoS One; 2018; 13(10):e0203823. PubMed ID: 30281670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]